Coverage News Update:

Effective January 1, 2022; Continuous Glucose Monitoring will be covered by Medi-Cal Rx as a pharmacy-billed medical supply benefit with an approved pharmacy prior authorization for Type 1 patients that meet criteria. Click here for the full update.

In The News:

FDA Grants Breakthrough Device Designation for Dexcom Hospital CGM System

Featured Resource:

ADA Standards of Medical Care: Recommendations for Continuous Glucose Monitoring

The American Diabetes Association (ADA) Standards of Medical Care represent the latest evidence-based recommendations for guiding clinical practice. According to the most recent edition of these guidelines, Level A evidence from the MOBILE study supports the use of real time continuous glucose monitoring (rtCGM) in patients with insulin-treated type 2 diabetes (T2D) regardless of regimen. The findings from the MOBILE study likewise demonstrate the value of rtCGM across typically underserved demographics of patients impacted by social determinants of health (SDOH). Taking the ADA recommendations into consideration, payers are formulating coverage policies that facilitate appropriate access to rtCGM, improved outcomes in T2D, and proven per-member-per-month (PMPM) cost savings.

Featured Publications

Recent News

		CMS revised Medicare coverage criteria for therapeutic CGMs. Most notably, eliminating a requirement that beneficiaries use four fingerstick tests per day prior to accessing CGM. Effective July 18, 2021. Centers for Medicare & Medicaid Services
		Real-time CGM lowers HbA1c, reduces ED visits in insulin-treated diabetes Endocrine Today